Table 2.
Renal insufficiency endpoint | Baseline no. (%) | Year 12 no. (%) |
---|---|---|
Measured GFR (iothalamate) | ||
>90 (CKD Stage 1) | 135 (56.0) | 32 (14.2) |
60–89 (CKD Stage 2) | 94 (39.0) | 81 (35.8) |
30–59 (CKD Stage 3) | 12 (5.0) | 55 (24.3) |
15–29 (CKD Stage 4) | 0 (0.0) | 16 (7.1) |
<15 (CKD Stage 5) or ESRD | 0 (0.0) | 42 (18.6) |
GFR decreased ≥ 30% | 143 (71.1) | |
GFR decreased ≥ 57% | 76 (40.4) | |
| ||
eGFR (MDRD formula) | ||
>90 (CKD Stage 1) | 96 (39.8) | 12(5.2) |
60–89 (CKD Stage 2) | 121 (50.2) | 92 (39.7) |
30–59 (CKD Stage 3) | 24 (10.0) | 64 (27.6) |
15–29 (CKD Stage 4) | 0 (0.0) | 22 (9.5) |
<15 (CKD Stage 5) or ESRD | 0 (0.0) | 42 (18.1) |
GFR decreased ≥ 30% | 139 (67.5) | |
GFR decreased ≥ 57% | 77 (38.7) | |
| ||
eGFR (CKD-EPI formula) | ||
>90 (CKD Stage 1) | 121 (50.2) | 20 (8.9) |
60–89 (CKD Stage 2) | 102 (42.3) | 80 (35.6) |
30–59 (CKD Stage 3) | 18 (7.5) | 57 (25.3) |
15–29 (CKD Stage 4) | 0 (0.0) | 26 (11.5) |
<15 (CKD Stage 5) or ESRD | 0 (0.0) | 42 (18.7) |
GFR decreased ≥ 30% | 140 (70.0) | |
GFR decreased ≥ 57% | 79 (39.7) |
GFR values in mL/min/1.73 m2